Evaluation of the additional actions and resource utilization required for the management of potential drug-drug interactions in HCV patients showing cardiovascular and central nervous system comorbidities, treated with sofosbuvir/velpatasvir compared to glecaprevir/ pibrentasvir in routine clinical practice in Spain.
